Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 11Lymphoid 4Gastrointestinal 2Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 140Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Trastuzumab 32Ramucirumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × alvocidib × Gastrointestinal × Clear all
NCT00331682 2014-05-28

Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00991952 2014-05-26

Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 8 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡